Michael Connarty: I know it is not a matter of nationality, but I remind the Secretary of State of the adage, “Beware of a Scotsman on the make”—even if he indeed left Scotland in 1978. Pfizer is in trouble. Its profits have dropped by 15% to
	£1.3 billion, and every time it takes over a company it is to seize a product. It was Lipitor—an anti-cholesterol drug—from Warner-Lambert; with Wyeth it was Enbrel, an arthritis drug, and then it shut Wyeth’s research. It shut its own research. There can be no guarantees that this company is after anything other than a tax haven. What can and will the Secretary of State do to stop that?